132 related articles for article (PubMed ID: 28131548)
21. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
[TBL] [Abstract][Full Text] [Related]
22. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
[TBL] [Abstract][Full Text] [Related]
23. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological targeting of differential DNA repair, radio-sensitizes WRN-deficient cancer cells in vitro and in vivo.
Gupta P; Saha B; Chattopadhyay S; Patro BS
Biochem Pharmacol; 2021 Apr; 186():114450. PubMed ID: 33571504
[TBL] [Abstract][Full Text] [Related]
25. Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines.
Ribeiro JC; Barnetson AR; Jackson P; Ow K; Links M; Russell PJ
Int J Radiat Biol; 1999 Apr; 75(4):481-92. PubMed ID: 10331854
[TBL] [Abstract][Full Text] [Related]
26. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
27. Novel Amidine Derivative K1586 Sensitizes Colorectal Cancer Cells to Ionizing Radiation by Inducing Chk1 Instability.
Kim HS; Park JE; Lee WH; Kwon YB; Seu YB; Kim KS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673980
[TBL] [Abstract][Full Text] [Related]
28. G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition.
Sturgeon CM; Roberge M
Cell Cycle; 2007 Mar; 6(5):572-5. PubMed ID: 17351346
[TBL] [Abstract][Full Text] [Related]
29. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
30. AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest.
Yu CC; Huang HB; Hung SK; Liao HF; Lee CC; Lin HY; Li SC; Ho HC; Hung CL; Su YC
PLoS One; 2016; 11(3):e0151942. PubMed ID: 27031247
[TBL] [Abstract][Full Text] [Related]
31. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
32. Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.
Mikami K; Medová M; Nisa L; Francica P; Glück AA; Tschan MP; Blaukat A; Bladt F; Aebersold DM; Zimmer Y
Mol Cancer Res; 2015 Dec; 13(12):1544-53. PubMed ID: 26358474
[TBL] [Abstract][Full Text] [Related]
33. Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment.
Chung SW; Kim GC; Kweon S; Lee H; Choi JU; Mahmud F; Chang HW; Kim JW; Son WC; Kim SY; Byun Y
Biomaterials; 2018 Nov; 182():35-43. PubMed ID: 30103170
[TBL] [Abstract][Full Text] [Related]
34. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
[TBL] [Abstract][Full Text] [Related]
35. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.
Tao Y; Leteur C; Yang C; Zhang P; Castedo M; Pierré A; Golsteyn RM; Bourhis J; Kroemer G; Deutsch E
Cell Cycle; 2009 Apr; 8(8):1196-205. PubMed ID: 19305158
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines.
Kim YM; Jeong IH; Pyo H
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e399-407. PubMed ID: 22417802
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia.
Jin T; Wang P; Long X; Jiang K; Song P; Wu W; Xu G; Zhou Y; Li J; Liu T
ChemMedChem; 2021 May; 16(9):1477-1487. PubMed ID: 33591599
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.
Samadder P; Suchánková T; Hylse O; Khirsariya P; Nikulenkov F; Drápela S; Straková N; Vaňhara P; Vašíčková K; Kolářová H; Binó L; Bittová M; Ovesná P; Kollár P; Fedr R; Ešner M; Jaroš J; Hampl A; Krejčí L; Paruch K; Souček K
Mol Cancer Ther; 2017 Sep; 16(9):1831-1842. PubMed ID: 28619751
[TBL] [Abstract][Full Text] [Related]
39. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
[TBL] [Abstract][Full Text] [Related]
40. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
